{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=16", "query": { "intervention": "pembrolizumab", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 1844, "total_pages": 185, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T19:32:52.810Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04781088", "title": "Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Floor Backes, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 38, "start_date": "2021-09-01", "completion_date": "2027-03-15", "has_results": true, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-27T19:32:52.810Z", "location_count": 2, "location_summary": "Columbus, Ohio • Pittsburgh, Pennsylvania", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04781088" }, { "nct_id": "NCT02840994", "title": "A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "CV301", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-12", "completion_date": "2020-01", "has_results": false, "last_update_posted_date": "2020-02-27", "last_synced_at": "2026-10-27T19:32:52.810Z", "location_count": 7, "location_summary": "Tampa, Florida • Indianapolis, Indiana • Metairie, Louisiana + 4 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02840994" }, { "nct_id": "NCT07566156", "title": "Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Cancer", "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Conventional Radiotherapy", "type": "RADIATION" }, { "name": "Hypofractionated Radiotherapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Mitomycin C", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2026-05-11", "completion_date": "2032-02-29", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-27T19:32:52.810Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • Santa Barbara, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Hinsdale", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07566156" }, { "nct_id": "NCT05846646", "title": "Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oligometastatic Disease" ], "interventions": [ { "name": "IMSA101", "type": "DRUG" }, { "name": "Immune checkpoint inhibitor", "type": "DRUG" }, { "name": "PULSAR", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "ImmuneSensor Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-06-28", "completion_date": "2024-09-16", "has_results": true, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-10-27T19:32:52.810Z", "location_count": 9, "location_summary": "Irvine, California • Kansas City, Kansas • New Brunswick, New Jersey + 5 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05846646" }, { "nct_id": "NCT05846659", "title": "Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oligoprogressive" ], "interventions": [ { "name": "IMSA101", "type": "DRUG" }, { "name": "Immune checkpoint inhibitor", "type": "DRUG" }, { "name": "PULSAR", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "ImmuneSensor Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2023-07-07", "completion_date": "2024-11-20", "has_results": true, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-27T19:32:52.810Z", "location_count": 14, "location_summary": "Irvine, California • Los Angeles, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05846659" }, { "nct_id": "NCT05785754", "title": "DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "DCSZ11", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Tebentafusp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DynamiCure Biotechnology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2023-06-28", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-10-27T19:32:52.810Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785754" }, { "nct_id": "NCT02546531", "title": "Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Solid Tumors", "Pancreatic Cancer" ], "interventions": [ { "name": "Defactinib", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2016-02-03", "completion_date": "2021-01-11", "has_results": false, "last_update_posted_date": "2021-07-20", "last_synced_at": "2026-10-27T19:32:52.810Z", "location_count": 2, "location_summary": "Rochester, Minnesota • St Louis, Missouri", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02546531" }, { "nct_id": "NCT04297605", "title": "Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed (Chemotherapy)", "type": "OTHER" }, { "name": "Nab-paclitaxel (Chemotherapy)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2020-05-15", "completion_date": "2028-01-30", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-27T19:32:52.810Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04297605" }, { "nct_id": "NCT05838768", "title": "Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers" ], "interventions": [ { "name": "HRO761", "type": "DRUG" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 123, "start_date": "2023-06-27", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-27T19:32:52.810Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05838768" }, { "nct_id": "NCT04454489", "title": "Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Metastatic Head-and-neck Squamous-cell Carcinoma", "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Pembrolizumab (immunotherapy)", "type": "DRUG" }, { "name": "Quad-shot palliative radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-02-25", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-27T19:32:52.810Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04454489" } ] }